Allogeneic blood transfusion alleviates hip joint pain induced by ankylosing spondylitis

doi:10.3969/j.issn.2095-4344.2014.09.026

Abstract

Abstract:

BACKGROUND: Pain is the main clinical manifestation for ankylosing spondylitis. At present, nonsteroid anti-inflammatory drugs are orally taken, but the effects are limited and toxic and side effects are more. Thus, there is no effective scheme for treatment of pain induced by ankylosing spondylitis.
OBJECTIVE: To investigate the correlation between postoperative joint pain alleviation and allogeneic blood transfusion, and the mechanisms.
METHODS: We retrospectively analyzed clinical data of 88 ankylosing spondylitis patients combined with kyphosis who received only one section of osteotomy surgery merging hip joint pain. We compared the visual analog scale score of hip joint and detected the variation of leucocytes, lymphocytes and immunoglobulin concentrations before and after the operation in the groups of fresh allogeneic whole blood transfusion, autologous whole blood transfusion, and mixed transfusion of allogeneic and autologous whole blood. Flow cytometry was used to analyze the number and ratio of peripheral blood Th17 cells and Treg cells which were both highly associated with autoimmune diseases.
RESULTS AND CONCLUSION: The symptom of hip arthralgia obviously improved in both groups transfused by fresh allogeneic whole blood or allogeneic-autologous mixed whole blood. However, no obvious variation was detected in leucocytes, lymphocytes and immunoglobin concentration. However, flow cytometry results indicated that Th17/Treg proportion associated with autoimmune diseases was increased remarkably in peripheral blood of ankylosing spondylitis patients. Results suggested that allogeneic whole blood transfusion can alleviate patients’
joint pain by correcting the imbalance of Th17/Treg which may improve their immune state.

中国组织工程研究杂志出版内容重点：人工关节；骨植入物；脊柱；骨折；内固定；数字化骨科；组织工程

全文链接：

Key words: spondylitis, ankylosing, blood transfusion, arthralgia, Th17 cells, T-lymphocytes, regulatory

CLC Number:

R318

Zhang Xin, Wang Peng, Wu Yan-feng, Yang Rui, Huang Lin, Tang Yong, Li Yu-xi, Gao Liang-bin, Shen Hui-yong . Allogeneic blood transfusion alleviates hip joint pain induced by ankylosing spondylitis[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(9): 1465-1470.

Figures/Tables 3

References

[1]Feldtkeller E, Khan MA, van der Heijde D,et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis.Rheumatol Int. 2003; 23(2):61-66.

[2]Zvyagin IV, Mamedov IZ, Britanova OV,et al. Contribution of functional KIR3DL1 to ankylosing spondylitis.Cell Mol Immunol. 2010;7(6):471-476.

[3]Braun J, Sieper J.Ankylosing spondylitis.Lancet. 2007; 369 (9570):1379-1390.

[4]白人骁,毕晓阳,张福江,等.关节成形术治疗强直性脊柱炎晚期严重髋关节畸形[J].中华骨科杂志,1999,19(7):400-403.

[5]高志国,于建华,徐世玺,等.强直性脊柱炎全髋关节置换术的常见问题及其处理[J].中华骨科杂志,2000,20(12):728-731.

[6]Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60(6):1647-1656.

[7]van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27(4):361-368.

[8]Benedek TG.How did ankylosing spondylitis become a separate disease. Clin Exp Rheumatol. 2009;27(4 Suppl 55): S3-9.

[9]Brewerton DA, Hart FD, Nicholls A,et al. Ankylosing spondylitis and HL-A 27.Lancet. 1973;1(7809):904-907.

[10]Mei Y, Pan F, Gao J, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis.Clin Rheumatol. 2011;30(2):269-273.

[11]Harrington LE, Hatton RD, Mangan PR,et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.Nat Immunol. 2005;6(11):1123-1132.

[12]Park H, Li Z, Yang XO,et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.Nat Immunol. 2005;6(11):1133-1141.

[13]Ghoreschi K, Laurence A, Yang XP,et al.T helper 17 cell heterogeneity and pathogenicity in autoimmune disease.Trends Immunol. 2011;32(9):395-401.

[14]Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses.Blood. 2005; 105(4):1815-1822.

[15]Takahashi T, Sakaguchi S.The role of regulatory T cells in controlling immunologic self-tolerance.Int Rev Cytol. 2003; 225:1-32.

[16]Sakaguchi S, Ono M, Setoguchi R,et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease.Immunol Rev. 2006;212:8-27.

[17]Wang X, Lin Z, Wei Q,et al. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis.Rheumatol Int. 2009;29(11):1343-1347.

[18]Iwakura Y, Ishigame H.The IL-23/IL-17 axis in inflammation.J Clin Invest. 2006;116(5):1218-1222.

[19]Boissier MC, Assier E, Falgarone G,et al. Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm.Joint Bone Spine. 2008; 75(4):373-375.

[20]Ehrenstein MR, Evans JG, Singh A,et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy.J Exp Med. 2004;200 (3): 277-285.

[21]Bettelli E, Carrier Y, Gao W,et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.Nature. 2006;441(7090):235-238.

[22]Langrish CL, Chen Y, Blumenschein WM,et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.J Exp Med. 2005;201(2):233-240.

[23]Murphy CA, Langrish CL, Chen Y,et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.J Exp Med. 2003;198(12):1951-1957.

[24]Taylan A, Sari I, Kozaci DL,et al. Evaluation of the T helper 17 axis in ankylosing spondylitis. Rheumatol Int. 2012;32(8): 2511-2515.

[25]Van bezooijen RL, Farih-Sips HC, Papapoulos SE,et al. Interleukin-17: A new bone acting cytokine in vitro.J Bone Miner Res. 1999;14(9):1513-1521.

[26]Chabaud M, Miossec P.The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model.Arthritis Rheum. 2001;44(6):1293-1303.

[27]Huang W, Schwarz EM.Mechanisms of bone resorption and new bone formation in spondyloarthropathies.Curr Rheumatol Rep. 2002;4(6):513-517.

[28]Rifas L, Arackal S.T cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen-activated protein kinase mechanism.Arthritis Rheum. 2003;48(4):993-1001.

[29]Poole AR.The histopathology of ankylosing spondylitis: are there unifying hypotheses. Am J Med Sci. 1998;316(4):228- 233.

[30]Bárdos T, Szabó Z, Czipri M,et al. A longitudinal study on an autoimmune murine model of ankylosing spondylitis.Ann Rheum Dis. 2005;64(7):981-987.

[31]Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balabce. Eur J Immunol. 2010;40(7):1830-1835.

[32]Nistala K, Wedderburn LR.Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology (Oxford). 2009;48(6):602-606.

[33]Zhou L, Lopes JE, Chong MM,et al.TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function.Nature. 2008;453(7192):236-240.

[34]Miceli-Richard C, Dougados M.NSAIDs in ankylosing spondylitis.Clin Exp Rheumatol. 2002;20(6 Suppl 28):S65-66.

[35]Barr A, Keat A.Spondyloarthritides: evolving therapies.Arthritis Res Ther. 2010;12(6):221.

[36]Gorman JD, Sack KE, Davis JC Jr.Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.N Engl J Med. 2002;346(18):1349-1356.

[37]Shaikh SA.Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment.J Can Chiropr Assoc. 2007;51(4): 249-260.

[38]Fouque-Aubert A, Jette-Paulin L, Combescure C,et al. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis. 2010;69(10):1756-1761.

[39]Miller EA, Ernst JD.Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed.J Clin Invest. 2009;119(5):1079-1082.

[40]Nacci F, Matucci-Cerinic M.Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-α) era.Best Pract Res Clin Rheumatol. 2011;25(3):375-388.